

## Confident prescribing demands a solid basis

Your decision to prescribe 'Tagamet' is supported by more than just highly effective therapy. Since its introduction in 1976 'Tagamet' has generated more experience than most other standard therapies.

Your patient is probably not concerned that he is just one of an estimated 15,000,000 who have now been treated with 'Tagamet' worldwide; that the use of 'Tagamet' is being systematically monitored on a scale probably larger than that of any other drug; nor that nearly 4,000 publications reflect the status of 'Tagamet' as one of the

most widely studied drugs in medical history.

All of these facts determine your confidence when you decide to prescribe 'Tagamet'.

Your patient's concern is simply that it works.

**Tagamet**   
cimetidine  
puts you in control of gastric acid

#### Prescribing Information

**Presentation** 'Tagamet' Tablets, PL 0002/0063, each containing 200 mg cimetidine. 112 (treatment pack), £16.30; 500, £72.75. 'Tagamet' Syrup, PL 0002/0073, containing 200 mg cimetidine per 5 ml. 200 ml, £7.86.

**Indications** Duodenal ulcer, benign gastric ulcer, reflux oesophagitis.

**Dosage** Duodenal ulcer: Adults, 400 mg b.d., with breakfast and at bedtime, or 200 mg t.d.s. with meals and 400 mg at bedtime.

(1.0 g/day) for at least 4 weeks (for full instructions see Data Sheet).

To prevent relapse, 400 mg at bedtime or 400 mg morning and at bedtime for at least 6 months. Benign gastric ulcer: Adults, 200 mg t.d.s. with meals and 400 mg at bedtime (1.0 g/day) for at least 6 weeks (for full instructions see Data Sheet).

Reflux oesophagitis: Adults, 400 mg t.d.s. with meals and 400 mg at bedtime (1.6 g/day) for 4 to 8 weeks.

**Cautions** Impaired renal function: reduce dosage (see Data Sheet).

Potential of oral anticoagulants and phenytoin (see Data Sheet).

Prolonged treatment: observe patients periodically. Exclude malignancy in gastric ulcer. Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation.

**Adverse reactions** Diarrhoea, dizziness, rash, tiredness. Rarely, mild gynaeomastia, reversible liver damage, confusional states (usually in the elderly or very ill), interstitial nephritis, acute pancreatitis.

**Legal category** POM. 1:2.82.

**SK&F**  
a SmithKline company

Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY. © 1982 Smith Kline & French Laboratories Limited  
'Tagamet' is a trade mark

TG-AD1161/2





# "WHAT GOES UP MUST COME DOWN"

**Presentation** White odourless aerosol foam containing hydrocortisone acetate 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed in each pack). Satisfactory response usually occurs within five to seven days. **Contra-indications and**

**Warnings**, etc. Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulas. General precautions common to all corticosteroid therapy should be observed during treatment with 'Colifoam'. Treatment should be administered with caution in patients with severe ulcerative diseases because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical**



# WRONG.

Isaac Newton got it wrong. At least as far as COLIFOAM is concerned.

In a comparative trial (Ruddell WSJ et al. Gut 1980; 21:885) involving 30 patients with distal colitis: "Eight patients in the enema group reported difficulty in retaining the treatment, whereas none of the 15 patients receiving the foam [COLIFOAM] experienced any difficulty,..."

COLIFOAM is far more convenient and far more comfortable to administer.

It is also highly effective. In the same

trial, COLIFOAM was shown to provide a slightly better objective improvement. The patients themselves reported an extremely significant preference ( $p < 0.05$ ) for the modern COLIFOAM treatment.

Surprisingly, these superior benefits do not mean that it is more expensive. In fact, COLIFOAM can cost up to 34% less per dose than a standard proprietary enema\*.

In terms of sheer convenience, patient comfort, cost and comparative efficacy – there is no better choice of treatment than COLIFOAM.

\*based on one application daily.



## Colifoam

hydrocortisone acetate foam.

**A CHANGE FOR THE BETTER IN DISTAL INFLAMMATORY BOWEL DISEASE.**

**precautions** Do not refrigerate, incinerate or puncture the aerosol can. Shake vigorously before use. Keep out of reach of children. **Package quantities** Aerosol canister containing 20g. (14 applications) plus a plastic applicator and illustrated leaflet. One applicatorful of 'Colifoam' provides a dose of approximately 90–110mg. of hydrocortisone acetate, similar to that used in a retention enema for the treatment of ulcerative colitis, sigmoiditis and proctitis.

**Product licence no.** 0036/0021.

**Basic NHS Cost** 20g (14 applications) plus applicator, £7.58.

Further information is available on request.

**Stafford-Miller Ltd.,**

Professional Relations Division,

Hatfield, Herts. AL10 0NZ.



# HEALING OF PEPTIC ULCER

"by restoring gastric  
physiology to normal"<sup>1</sup>

"Carbenoxolone ... acts by restoring gastric physiology to normal in strengthening the mucosal barrier, rather than by creating a non-physiological situation of hypochlorhydria, such as antacids and H<sub>2</sub> receptor antagonists produce."<sup>1</sup>

1. XI Int. Cong. Gastroenterology,  
Hamburg, June 1980.


- Increased mucus production
- Reduced epithelial cell loss
- Reduced peptic secretion and activity



**BIOGASTRONE**  
carbenoxolone  
for gastric ulcer



**DUOGASTRONE**  
carbenoxolone  
for duodenal ulcer



Further information available from Winthrop Laboratories, Surbiton-upon-Thames,  
Surrey KT6 4PH. See prescribing data overleaf.

**WINTHROP**

# BIOGASTRONE

**carbenoxolone**  
for gastric ulcer

Carbenoxolone sodium BP 50 mg tablets.  
PL 0071/5902. Bottles of 100. Basic NHS cost: 1  
week's treatment \$2.21 (21 tablets) — \$4.42 (42  
tablets).

**Adult dose:** 2 tablets t.i.d. after meals for the first  
week then 1 tablet t.i.d. until ulcer is healed  
(usually 4-6 weeks).

# DUOGASTRONE

**carbenoxolone**  
for duodenal ulcer

Carbenoxolone sodium BP. 50 mg  
position-release capsules. Bottles of 28.  
PL 0071/5903. Basic NHS cost: 1 day's treatment  
(4 capsules) 85p.

**Adult dose:** 1 capsule swallowed whole and  
unbroken with liquid q.i.d., 15-30 minutes before  
meals. Patients may continue to take antacids  
but anticholinergic drugs should be  
discontinued. Treatment should continue for 6-12  
weeks.

## **Safety factors: Biogastrone and Duogastrone**

**Contra-indications.** Severe cardiac, renal or  
hepatic failure. Patients on digitalis therapy,  
unless serum electrolyte levels are monitored  
weekly and measures taken to prevent the  
development of hypokalaemia.

**Precautions.** Special care should be exercised  
with patients pre-disposed to sodium and water  
retention, potassium loss and hypertension (e.g.  
the elderly and those with cardiac, renal or  
hepatic disease) since carbenoxolone can  
induce similar changes. Regular monitoring of  
weight and blood pressure, which should  
indicate such effects, is advisable for all patients.  
A thiazide diuretic should be administered if  
oedema or hypertension occurs.

(Spironolactone should not be used because it  
hinders the therapeutic action of  
carbenoxolone). Potassium loss should be  
corrected by the administration of oral  
supplements. No teratogenic effects have been  
reported with carbenoxolone sodium, but  
careful consideration should be given before  
prescribing Biogastrone, Duogastrone or  
Pyrogastrone for women who may become  
pregnant.

Biogastrone and Duogastrone are registered  
trade marks.  
Made under licence from Biorex Laboratories,  
Brit. Pat. No. 1093286.  
Further information available from Winthrop  
Laboratories, Surbiton-upon-Thames, Surrey  
KT6 4PH.

 **WINTHROP**

## Gastrointestinal and Related Hormones

*The Proceedings of a Symposium organised by  
The Association of Clinical Pathologists*

*Edited by G. Walters and S. R. Bloom*

### CONTENTS

Editor's foreword • The endocrine versatility  
of the gut: general and evolutionary aspects of  
the active peptides of the gastrointestinal tract  
• Visualisation of the diffuse endocrine  
system • Neurotensin • Pathophysiology of  
gastrin and secretin • The measurement of  
cholecystokinin • Gastric inhibitory poly-  
peptide (GIP) • The enteroinsular axis •  
Pancreatic polypeptide • Importance of the  
jejunal hormone motilin • Gut glucagon-like  
immunoreactants (GLIs) and other enteric  
glucagon-like peptides • Vasoactive intestinal  
peptide (VIP) • Brain and gut peptides • gut  
hormones in gastrointestinal disease •  
Clinical features and diagnosis of alimentary  
endocrine tumours •

**Price: Inland £5.00;  
Abroad US\$12.50,  
including postage**

Payment must be enclosed with order or a surcharge of 50p will be  
made for rendering invoices and statements.

The Publisher, *Journal of Clinical  
Pathology* BMA House, Tavistock  
Square, London WC1H 9JR



"I feel I'm so full I could burst!  
With this overblown stomach I'm cursed."  
The Doctor smiled sweetly,  
Then murmured discreetly,  
"Well, we'd better try Maxolon first."

For relief from  
heartburn and flatulence

# Maxolon

metoclopramide

## PRESCRIBING INFORMATION

**Indications**  
Dyspepsia, heartburn and flatulence associated with the following conditions e.g. Reflux oesophagitis. Gastritis, Hiatus hernia. Peptic ulcer. Nausea and vomiting associated with e.g. Gastro-intestinal disorders.

**Adult dosage (Oral, IM or IV)**

Total daily dosage of Maxolon especially for children and young adults should not normally exceed 0.5mg/kg body-weight.

Adults 10mg 3 times a day.  
Young adults (15-20 years) 5-10mg 3 times a day commencing at the lower dosage.

For dosage in children please consult Data Sheet.

**Side-effects and Precautions**  
There are no absolute contra-indications to the use of Maxolon.

If vomiting persists the patient should be re-assessed to exclude the possibility of an underlying disorder, eg. cerebral irritation. Various extra-pyramidal reactions to Maxolon, usually of the dystonic type, have been reported. The incidence of these reactions in children and young adults may be increased if daily dosages higher than 0.5mg/kg body-weight are administered. The majority of reactions occur within 36 hours of starting treatment and the

effects usually disappear within 24 hours of withdrawal of the drug. Should treatment of a reaction be required, an anticholinergic anti-Parkinsonian drug or a benzodiazepine may be used. Since extra-pyramidal symptoms may occur with both Maxolon and phenothiazines, care should be exercised in the event of both drugs being prescribed concurrently.

Raised serum prolactin levels have been observed during metoclopramide therapy: this effect is similar to that noted with many other compounds. Maxolon's action on the gastro-intestinal tract is antagonised by anticholinergics. Although animal tests in several mammalian

species have shown no teratogenic effects, treatment with Maxolon is not advised during the first trimester of pregnancy.

Following operations such as pyloroplasty or gut anastomosis Maxolon therapy should be withheld for three or four days as vigorous muscular contractions may not help healing.

**Availability and NHS Prices**  
Tablets 10mg (£8.50 for 100).  
Syrup 5mg/5ml (£2.92 for 200ml).  
Ampoules for injection 10mg (£2.34 for 10).  
A paediatric liquid presentation is also available.  
Prices correct at May 1982.

Further information is available on request to the company.



**Beecham Research Laboratories**

Brentford, England.  
Maxolon and the BRL logo are trade marks.

PL 0038/0095 0098 5040 5041.

# A fresh approach to peptic ulcers



## **New** **Antepsin** **sucralfate** non-systemic ulcer healer

### Prescribing Information

**Presentation** Antepsin Tablets 1 gram are white, oblong, biconvex, uncoated tablets scored and embossed 1239 on one side and Ayerst on the other. Each tablet contains 1 gram sucralfate. **Uses** For the treatment of duodenal ulcer, gastric ulcer and chronic gastritis. **Dosage and Administration** For oral administration. **Adults** - Usual dose 1 gram 4 times a day. Maximum daily dose 8 grams. Four to six weeks treatment is usually needed for ulcer healing but up to twelve weeks may be necessary in resistant cases. Antacids may be used as required.

\* ANTEPSIN is a registered Trade Mark.

for relief of pain. **Contra-Indications, Precautions, Warnings, etc.** **Contra-Indications** There are no known contra-indications. **Precautions** 1. Concomitant administration with some oral anti-infectives such as tetracyclines may interfere with absorption of the latter. 2. The product should only be used with caution in patients with renal dysfunction. 3. As with all medicines, Antepsin should not be used in early pregnancy unless considered essential. **Side Effects** A low incidence of mild side effects, e.g. constipation, has been reported. **Legal Category** POM. **Package Quantities** Antepsin 1 gram - Securitainers of 100. **Pharmaceutical Precautions** No special

Further information is available on request to the Company.

requirements for storage are necessary. **Product Licence Numbers** PL No 0607/0045 PA No 149/4/2 Basic N.H.S. Price Average daily cost 50p



**Ayerst**  
International

Ayerst Laboratories Ltd.,  
South Way, Andover, Hampshire SP10 5LT.

Telephone: 0264 58711.


**Distributors in Ireland:** Ayerst Laboratories Ltd.,  
765 South Circular Road, Islandbridge, Dublin 8.

# DE-NOL<sup>®</sup>

Tri-potassium di-citrate bismuthate (colloidal bismuth subcitrate)

## protects longer

In both gastric and duodenal ulcer, De-Nol is just as effective as cimetidine,<sup>1-4</sup> has a non-systemic mode of action and has a lower relapse rate in duodenal ulcer.<sup>1</sup>



**References:** 1. Martin et al, Lancet 1, 7-10(1981). 2. Kang et al, Aust.N.Z.Med. 10, 111(1980). 3. Cowen et al, Aust.N.Z.Med. 10, 364(1980). 4. Tanner et al, Med.J.Aust. 1, 1-2(1979).

**Prescribing information** De-Nol contains 120mg tri-potassium di-citrate bismuthate (as  $\text{Bi}_2\text{O}_3$ ) per 5ml. For the treatment of gastric and duodenal ulcers. Oral administration, usually 5ml diluted with 15ml water four times a day on an empty stomach, half an hour before each of the three main meals and two hours after the last meal of the day. Contra-indicated on theoretical grounds in cases of severe renal insufficiency and in pregnancy. De-Nol may inhibit the efficacy of orally administered tetracyclines. Blackening of the stool can occur and darkening of the tongue has been reported. 28 day (560ml) treatment pack £10.19. P/L No. 0166/5204.

**Brocades|Great Britain|Limited** Brocades House, Pyrford Road, West Byfleet, Surrey.



# Prescribing Information

## NEW Zantac


### RANITIDINE

#### Uses

**Indications:** Zantac Tablets are indicated for the treatment of duodenal ulcer, benign gastric ulcer, post-operative ulcer, reflux oesophagitis and the Zollinger-Ellison syndrome.

**Mode of action:** Zantac is a highly effective, rapidly acting histamine H<sub>2</sub>-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Zantac has a relatively long duration of action and so a single dose effectively suppresses gastric acid secretion for twelve hours.

*Fast*



*Simple*

#### Dosage and administration

**Adults:** The usual dosage is one 150 mg tablet twice daily, taken in the morning and before retiring. It is not necessary to time the dose in relation to meals. In most cases of duodenal ulcer, benign gastric ulcer and post-operative ulcer, healing occurs in four weeks. In the small number of patients whose ulcers have not fully healed, healing usually occurs after a further course of treatment. Maintenance treatment at a reduced dosage of one 150 mg tablet at bedtime is recommended for patients who have responded to short-term therapy, particularly those with a history of recurrent ulcer. In the management of reflux oesophagitis, the recommended course of treatment is one 150 mg tablet twice daily for up to 8 weeks.

In patients with Zollinger-Ellison syndrome, the starting dose is 150 mg three times daily and this may be increased, as necessary, to 900 mg per day. **Children:** Experience with Zantac Tablets in children is limited and such use has not been fully evaluated in clinical studies. It has, however, been used successfully in children aged 8-18 years in doses up to 150 mg twice daily without adverse effect.

#### Contra-indications

There are no known contra-indications to the use of Zantac Tablets.

#### Precautions

Treatment with a histamine H<sub>2</sub>-antagonist may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition.

Accordingly, where gastric ulcer is suspected the possibility of malignancy should be excluded before therapy with Zantac Tablets is instituted.

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased and prolonged in patients with severe renal failure. Accordingly, it is recommended that the therapeutic regimen for Zantac in such patients be 150 mg at night for 4 to 8 weeks. The same dose should be used for maintenance treatment should this be deemed necessary. If an ulcer has not healed after treatment for 4 to 8 weeks and the condition of the patient requires it, the standard dosage regimen of 150 mg twice daily should be instituted, followed, if need be, by maintenance treatment at 150 mg at night.

Although the incidence of adverse reactions in clinical trials of one year's duration and longer has been very low and no serious side effects have been reported with Zantac treatment, care should be taken to carry out periodic examinations of patients on prolonged maintenance treatment with the drug as a safeguard against the occurrence of unforeseeable consequences of drug treatment.

Like other drugs, Zantac should be used during pregnancy and nursing only if strictly necessary. Zantac is secreted in breast milk in lactating mothers but the clinical significance of this has not been fully evaluated.

#### Side effects

No serious adverse effects have been reported to date in patients treated with Zantac Tablets. There has been no clinically significant interference with endocrine, gonadal or liver function, nor has the drug adversely affected the central nervous system even in elderly patients.

#### Further information

**Drug interactions:** Ranitidine does not inhibit the cytochrome P450-linked mixed function oxygenase enzyme system in the liver and therefore does not interfere with the effects of the many drugs which are metabolised by this enzyme system. For example, there is no interaction with warfarin or diazepam.

**Pharmacokinetics:** Absorption of ranitidine after oral administration is rapid and peak plasma concentrations are usually achieved within two hours of administration. Absorption is not impaired by food or antacids. The elimination half-life of ranitidine is approximately two hours. Ranitidine is excreted via the kidneys mainly as the free drug and in minor amounts as metabolites. Its major metabolite is an N-oxide and there are smaller quantities of S-oxide and desmethyl ranitidine. The 24-hour urinary recovery of free ranitidine and its metabolites is about 40% with orally administered drug.

**Use in renal transplants:** Zantac has been used without adverse effect in patients with renal transplants.

**Product licence number** 0004/0279

**Basic NHS cost** (exclusive of VAT) 60 tablets £27.43.

**References:** 1. Data on file, Glaxo Group Research. 2. Bories, P *et al.*, Lancet 1980; 2 (8197):755. 3. Peden, N.R. *et al.*, Acta Endocrinologica 1981; 96:564-568. 4. Nelis, G.F. and Van de Meene, J.G.C., Postgrad. Med J. 1980; 56:478-480. 5. Henry, D.A. *et al.*, BrMed J. 1980; 2:775-777.

# Glaxo

Glaxo Laboratories Ltd., Greenford,  
Middlesex UB6 0HE.

A high-contrast, black and white image featuring a bright, diagonal streak of light that tapers towards the bottom right corner. The background is dark and filled with numerous small, white specks, resembling a starry night sky or a microscopic view. The streak itself has a soft, glowing edge, giving it a sense of depth and movement.

# The fast, simple and promote peptic

FOR PRESCRIBING INFORMATION SEE OVERLEAF

# and specific way to ulcer healing



**80% ulcers healed in one month<sup>1</sup>**

Rapid relief of pain, rapid healing of the ulcer.

**No dosage simpler in peptic ulcer treatment**


Specifically developed as b.d. treatment.

**The benefits of highly specific H<sub>2</sub> blockade**

Zantac treatment has not been shown to affect the central nervous system<sup>1,2</sup> to exert anti-androgenic effects<sup>3,4</sup> or to cause drug interaction<sup>5</sup>

**NEW**  
**Zantac**  
RANITIDINE

**A British advance from Glaxo**



# COLPERMIN CALMS THE IRRITABLE BOWEL

enteric-coated peppermint oil

Now for the first time, the well-proven therapeutic agent peppermint oil, can be delivered direct to the colon.

Colpermin, a newly developed enteric-coated capsule, delivers the oil precisely

where it is needed. This provides an improved, rapid, and highly effective method of relieving spasmodic pain, distension and disturbed bowel habit - the dominant symptoms of the irritable bowel syndrome.

**Presentation:** Enteric coated gelatine capsule. Each contains 0.2 ml standardised peppermint oil B.P. Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should not be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe.

The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years. **Contraindications, Warnings, etc. Precautions:** The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule.

Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** \$10.00 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.

**Tillotts**  
LABORATORIES

# The many faces of Crohn's disease. And one face of its treatment.

Salazopyrin has long been established as standard treatment for ulcerative colitis and there is now further evidence to support its use as a first-line therapy for active Crohn's disease.

Now a double-blind study<sup>(1)</sup> has shown that 62% of Salazopyrin-treated patients responded favourably (at least 25% reduction in Crohn's disease activity) compared with only 8% of patients given placebo.

This supports the findings of a major study<sup>(2)</sup> in the USA, the NCCDS\* involving some 569 patients, which compared Salazopyrin with azathioprine and prednisone both as short-term treatments to suppress acute disease and as long-term prophylactics against relapse. For active disease both Salazopyrin and prednisone were superior to placebo and in patients not previously treated with drugs or surgery, only Salazopyrin was superior to placebo.

Salazopyrin was also by far the least toxic of the drugs tested, which "...together with evidence of its usefulness, particularly for control of disease involving the colon, indicates sulphasalazine as the drug of choice for initial therapy of such patients."

\*National Cooperative Crohn's Disease Study.

## SALAZOPYRIN sulphasalazine

**YOUR BEST STARTING POINT IN ACTIVE  
CROHN'S DISEASE.**

### Prescribing Information Dosage and Administration

**Plain or EN Tablets:** In acute moderate attacks 2-4 tablets 4 times a day. In severe attacks steroids should also be given. After 2-3 weeks the dose may gradually be reduced to the maintenance level of 3-4 tablets daily which should be given indefinitely. **Suppositories:** Two inserted morning and night, the dose being gradually reduced after 3 weeks as improvement occurs.

**Enema:** One enema should be given daily preferably at bed time. This preparation contains an adult dose of Salazopyrin. Patient instructions are enclosed in each box. **Children:** Reduce the adult dose on the basis of body weight.

### Contra-Indications, warnings etc.

**Contra-Indications:** Contra-indicated in sensitivity to salicylates and sulphonamides. Infants under 2 years. **Enema only:** Sensitivity to parabens

**Adverse Reactions:** Side effects common to salicylates or sulphonamides may occur. Most commonly these are nausea, loss of appetite and raised temperature which may be relieved on reduction of dose, use of EN tablets, enema or suppositories. If serious reactions occur the drug should be discontinued.

Rarely the following adverse reactions have been reported. **Haematological:** e.g. Heinz body anaemia, haemolytic anaemia, leucopenia, agranulocytosis and aplastic anaemia. **Hypersensitivity:** e.g. Rash, fever.

**Gastrointestinal:** e.g. Impaired folate uptake, stomatitis. **C.N.S.:** e.g. Headache, peripheral neuropathy. **Fertility:** Reversible oligospermia. **Renal:** e.g. Proteinuria, crystalluria. **Also:** Stevens-Johnson syndrome and lung complications e.g. Fibrosing alveolitis.

### Precautions:

Care in cases of porphyria, allergic, renal or hepatic disease, glucose 6-PD deficiency. Blood checks should be made initially and periodically.

### Pregnancy and Lactation:

While the ingestion of drugs in these situations may be undesirable, the severe exacerbations of the disease which can occur commends the continuance of therapy. Long clinical usage and experimental studies have failed to reveal teratogenic or icteric hazards. The amounts of drug present in the milk should not present a risk to a healthy infant.

### Packages & Prices:

Plain Tablets (0.5g): 100 & 500: £6.10 for 100. EN Tablets (0.5g): 100 & 500: £7.90 for 100. Suppositories (0.5g): 10 & 50: £2.55 for 10. Enemas (3.0g): 7: £10.80 for 7.

### Product Licence Numbers:

Plain Tablets 0009/5006 EN Tablets 0009/5007. Suppositories 0009/5008 Enema 0009/0023.

1) Gut (1981) 22, 404-409.

2) Gastroenterology (1979) 77, 847 et seq.



**Pharmacia**

Salazopyrin (regd) sulphasalazine, is a product of Pharmacia (Great Britain) Ltd, Prince Regent Rd, Hounslow Middlesex TW3 1NE. Tel: 01-572 7321. Further information is available on request from the Company.





# COLPERMIN CALMS THE IRRITABLE BOWEL

enteric-coated peppermint oil

Now for the first time, the well-proven therapeutic agent peppermint oil, can be delivered direct to the colon.

Colpermin, a newly developed enteric-coated capsule, delivers the oil precisely

where it is needed. This provides an improved, rapid, and highly effective method of relieving spasmodic pain, distension and disturbed bowel habit - the dominant symptoms of the irritable bowel syndrome.


**Presentation:** Enteric coated gelatine capsule. Each contains 0.2 ml standardised peppermint oil B.P. Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should not be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe.

The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years. **Contraindications, Warnings, etc. Precautions:** The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule.

Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424-0009. **Basic NHS Cost:** £10.00 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.

**Tillotts**  
LABORATORIES

# **Reflux oesophagitis** **more than a little bit of acid**



**Bile and pepsin**  
**Oesophageal sensitivity**  
**Inflammation**  
**Erosion**  
**Ulceration**

## **PYROGASTRONE**

carbenoxolone/magnesium trisilicate/dried aluminium hydroxide gel

**more than an antacid**  
**-a positive healing treatment**

Pyrogastrone is a registered trade mark. Made under licence from Biorex Laboratories, Brit. Pat. No. 1390683. Full information from Winthrop Laboratories, Surbiton-upon-Thames, Surrey. **WINTHROP**

# Gastro- enterology

*Recent titles*

## Abdominal Computer Tomography

With the collaboration of G. Marchal, G. Wilms  
1980. 315 figures in 585 separate illustrations. XI, 185 pages  
(Atlas of Pathological Computer Tomography, Volume 2)  
Cloth DM 198,-; approx. US \$ 88.00;  
approx. £ 46.10. ISBN 3-540-10093-8

## Artificial Liver Support

Editors: G. Brunner, F.W. Schmidt  
1981. 156 figures, 69 tables.  
XXI, 332 pages  
Cloth DM 98,-; approx. US \$ 43.60;  
approx. £ 22.80. ISBN 3-540-10591-3

H.D. Becker, W.F. Caspary

## Postgastrectomy and Postvagotomy Syndromes

1980. 84 figures, (mainly in 2 colors), 55 tables. XII, 188 pages  
Cloth DM 136,-; approx. US \$ 60.40;  
approx. £ 31.70. ISBN 3-540-09445-8

## Chemotherapy and Radiotherapy of Gastrointestinal Tumors

Editor: H.O. Klein  
1981. 38 figures, 59 tables.  
VII, 112 pages  
(Recent Results in Cancer Research, Volume 79)  
Cloth DM 58,-; approx. US \$ 25.80;  
approx. £ 13.50. ISBN 3-540-10938-2

## Controversies in Acute Pancreatitis

Editor: L.F. Hollender  
1982. 87 figures, 124 tables.  
XVIII, 344 pages  
DM 98,-; approx. US \$ 43.60;  
approx. £ 22.80. ISBN 3-540-11410-6

H.M. Delany, R.S. Jason

## Abdominal Trauma

Surgical and Radiologic Diagnosis  
With contributions by N. Carnevale, W. Delph, C.M. Moss, A. Rudavsky  
1981. 259 figures. XVI, 224 pages  
Cloth DM 98,-; approx. US \$ 43.60;  
approx. £ 22.80. ISBN 3-540-90502-2

## Endoscopy and Biopsy in Gastroenterology

Techniques and Indications  
Editors: P. Frühmorgen, M. Classen  
Translated from the German by  
H.V. Ammon, K.H. Soergel  
With contributions by numerous experts.  
With a Foreword by L. Demling  
1980. 108 figures, 24 tables.  
X, 198 pages  
DM 28,-; approx. US \$ 12.50;  
approx. £ 6.60. ISBN 3-540-09645-0

R.E. Hermann

## Manual of Surgery of the Gallbladder, Bile Ducts and Exocrine Pancreas

With contributions by A.M. Cooperman, C.B. Esselstyn jr., E. Steiger, R.T. Holzbach  
1979. 197 figures, 16 tables.  
XIV, 306 pages  
(Comprehensive Manuals of Surgical Specialties)  
Cloth DM 176.40; approx. US \$ 78.40;  
approx. £ 41.10. ISBN 3-540-90351-8

## Iatrogenic Gastrointestinal Complications

Editors: M. A. Meyers, G. G. Ghahremani  
1981. 587 figures. XII, 307 pages  
(Radiology of Iatrogenic Disorders)  
Cloth DM 99.50; approx. US \$ 44.20;  
approx. £ 23.20. ISBN 3-540-90505-7

## Immunological Aspects of Liver Disease

Editors: H.C. Thomas, P.A. Miescher, H.J. Mueller-Eberhard  
1982. 21 figures, 17 tables.  
VI, 216 pages  
DM 42,-; approx. US \$ 18.70;  
approx. £ 9.80. ISBN 3-540-11310-X

W.P. Longmire, R.K. Tompkins

## Manual of Liver Surgery

Illustrated by T. Bloodhart  
1981. 230 figures (142 figures in full color). XVII, 267 pages  
(Comprehensive Manuals of Surgical Specialties)  
Cloth DM 285,-; approx. US \$ 126.60;  
approx. £ 66.30. ISBN 3-540-90212-0

G.P. Marzoli, S. Vesentini

## Warren's Operation

With the cooperation of F. Frasson, G. Fugazzola, G. Mangiante, R. Maso  
Foreword by A. Dagradi  
1981. 46 figures. XII, 77 pages  
Cloth DM 86,-; approx. US \$ 38.20;  
approx. £ 20.00. ISBN 3-540-10785-1

M.A. Meyers

## Dynamic Radiology of the Abdomen

Normal and Pathologic Anatomy  
2nd edition. 1982. 1006 figures  
(17 figures in full color)  
XV, 396 pages  
Cloth DM 138,-; approx. US \$ 64.30;  
approx. £ 32.10. ISBN 3-540-90629-0

M.L. Skolnick

## Real-Time Ultrasound Imaging in the Abdomen

1981. 386 figures. XI, 241 pages  
Cloth DM 85,-; approx. US \$ 37.80;  
approx. £ 19.80. ISBN 3-540-90570-7

## Topics in Acute and Chronic Pancreatitis

Proceedings of the International Meeting  
held in Padenghe sul Garda (Italy),  
September 14-15, 1979  
Editors: L.A. Scuro, A. Dagradi  
Co-Editors: G.P. Marzoli, P. Pederzoli,  
G. Cavallini, C. Banterle  
1981. 95 figures, 64 tables.  
XII, 265 pages  
DM 60,-; approx. US \$ 26.70;  
approx. £ 14.00. ISBN 3-540-10439-9

C.E. Welch, L.W. Ottinger, J.P. Welch

## Manual of Lower Gastrointestinal Surgery


1980. 215 figures, 138 figures in color, 7 tables. XVI, 276 pages  
(Comprehensive Manuals of Surgical Specialties)  
Cloth DM 169,-; approx. US \$ 75.10;  
approx. £ 39.40. ISBN 3-540-90205-8



Springer-Verlag  
Berlin  
Heidelberg  
New York

Heidelberger Platz 3, D-1000 Berlin 33 -  
175 Fifth Ave., New York, NY 10010





# COLPERMIN CALMS THE IRRITABLE BOWEL

enteric-coated peppermint oil

Now for the first time, the well-proven therapeutic agent peppermint oil, can be delivered direct to the colon.

Colpermin, a newly developed enteric-coated capsule, delivers the oil precisely

where it is needed. This provides an improved, rapid, and highly effective method of relieving spasmodic pain, distension and disturbed bowel habit - the dominant symptoms of the irritable bowel syndrome.

**Presentation:** Enteric coated gelatine capsule. Each contains 0.2 ml standardised peppermint oil B.P. Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should not be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe.

The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years. **Contraindications, Warnings, etc. Precautions:** The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule.

Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £10.00 per 100 UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.



#### Indications

Intravenous sedative cover before and during unpleasant surgical and medical procedures

#### Dosage

0.2 mg/kg body-weight. The usual adult dose is 10–20 mg but more may be needed on occasions. In elderly patients half the usual adult dose

#### Administration

With the patient in the supine position, the injection should be given *slowly* (0.5 ml Valium Roche ampoule solution per half-minute) into a large vein of the antecubital fossa until the patient becomes drowsy, his speech becomes slurred and there is ptosis. He should still be able to respond to requests. Provided these conditions for administration are adhered to the rare possibility of hypotension or apnoea occurring will be greatly diminished. A second person should be present and resuscitation facilities should be available.

#### Precautions and side-effects

Patients should not be allowed to leave the surgery until one hour at least has elapsed from the time of injection and should always be accompanied by a responsible adult, with a warning not to drive or operate machinery for the rest of the day and to avoid alcohol. In patients with organic cerebral changes or with cardiorespiratory insufficiency IV injections of Valium Roche should not be employed unless in an emergency or in hospital if indicated and then should be given slowly and in reduced dosage. The possibility of intensified sedative effects and severe respiratory and cardiovascular depression should be considered if central depressant drugs are given, particularly by parenteral route, in conjunction with Valium Roche for Injection. Valium Roche should not be given in early pregnancy unless absolutely indicated. Intravenous injection may be associated with local reactions, including thrombophlebitis.

#### Presentation

Ampoules containing 10 mg diazepam in 2 ml and 20 mg in 4 ml, in packings of 10.

#### Product Licence Numbers

0031/0068 (ampoules 10 mg);  
0031/5128 (ampoules 20 mg)

#### Basic NHS Cost

Ampoules 10 mg x 10 £2.64  
Ampoules 20 mg x 10 £3.90

#### References

- 1 Brit med J. 1976; 2: 20.
- 2 Brit J Hosp Med. 1976; 16: 7.
- 3 Scand J Gastroent. 1979; 14: 747.
- 4 Scand J Gastroent. 1978; 13: 33.
- 5 Gut. 1976; 17: 655.
- 6 Brit J Hosp Med. 1971; 6 (Suppl): 52.
- 7 Amer J Gastroent. 1976; 66: 523.
- 8 Amer J med Sci. 1974; 267: 151.
- 9 Gut. 1976; 17: 975.
- 10 Advanced Medicine. 1978; No 14, p19.

# Intravenous Valium Roche

the preferred sedative  
for gastro-intestinal  
endoscopy



Vast would be an apt description of the experience with intravenous Valium Roche in gastro-intestinal endoscopy – an experience which covers the range of procedures and patients of all age groups.\* Endoscopy without premedication is for many patients an unpleasant experience.<sup>1</sup> Intravenous Valium Roche sedation improves patient acceptance without impairing their ability to co-operate. Keeping medication to a minimum is particularly important for out-patients<sup>2</sup> and avoidance of analgesics leads to faster recovery times.<sup>3</sup> In certain circumstances where prolonged intubation is required or pain from an operative procedure likely, the addition of a narcotic analgesic such as pethidine may be desirable.<sup>4</sup> Neuroleptanalgesia has also been used to good effect with intravenous Valium Roche.<sup>5</sup> The amnesic effect of intravenous Valium Roche undoubtedly contributes to the excellent acceptance by patients and their willingness to undergo repeat procedures.<sup>6</sup> The shortness of the amnesic effect is a boon for the operator too when treating out-patients. Age is no barrier to intravenous Valium Roche sedation for gastro-intestinal endoscopy.\* Whether the patient is six weeks or 103-years-old favourable results have been obtained.<sup>7</sup> This is true also for many poor-risk patients including those with liver disease in whom intravenous Valium Roche has been extensively used.<sup>8-10</sup> The dosage must, of course, be adjusted to the patient's needs and the necessary precautions observed.

\*Annotated bibliography of references available on request.

# Intravenous Valium Roche

diazepam

where experience  
counts

ROCHE

Roche Products Limited  
PO Box 8, Welwyn Garden City  
Hertfordshire AL7 3AY

Valium is a trade mark  
J954232 382

## International Journal of Gastroenterology

**Digestion** is a leading medical journal publishing research reports on diseases and pathophysiology of the gastrointestinal tract, liver and pancreas and on gastrointestinal endocrinology. Papers cover investigative physiology in humans and animals, metabolic studies, and extensive clinical work on the etiology, diagnosis, and therapy of human diseases. The journal's coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.

**Digestion**

☐ Please send examination copy

☐ Please enter my subscription beginning with vol. \_\_\_\_\_

☐ Institutional subscription ☐ Check enclosed

☐ Personal subscription ☐ Please bill me

Name and exact postal address \_\_\_\_\_





# The synthetic absorbable which ties easily..

## even in the presence of body fluids.

Coated VICRYL Polyglactin 910 ties down with less force than uncoated synthetic absorbables. Knot tension can be adjusted giving precise knot placement—even in the presence of body fluids.

This absorbable coating also maintains its lubricity in tissue, dramatically reducing the sawing action and drag previously associated with braided synthetic

absorbable sutures.

Whilst the strength retention in tissue of Coated VICRYL Sutures is high, with 55% still remaining at 14 days, total

absorption is usually complete between the 60th and 90th day.

Now available in a range of over ninety different products utilising a wide range of the finest ETHICON\* Eyeless Needles.

**Coated VICRYL\***  
(polyglactin 910) sutures

**ETHICON**

ETHICON Ltd., P.O. Box 408, Bankhead Avenue,  
Edinburgh EH11 4HE, Scotland.

\*Trade mark ©ETHICON Ltd 1982

TECHNICAL DATA OVER LEAF

Printed in Great Britain

## TECHNICAL DATA

---

# STERILISED ABSORBABLE SYNTHETIC SUTURE COATED POLYGLACTIN 910 VICRYL \*

---

**Presentation** The basic VICRYL (Polyglactin 910) Suture is prepared from a copolymer of glycolide and lactide. The substances are derived respectively from glycolic and lactic acids. The empirical formula of the copolymer is  $(C_2H_2O_2)_m(C_3H_4O_2)_n$ .

Coated VICRYL (Polyglactin 910) Sutures are obtained by coating the braided suture material with a mixture composed of a copolymer of glycolide and lactide and an equal amount of calcium stearate. This coating does not affect the biological properties of the suture.

VICRYL (Polyglactin 910) Sutures are coloured by adding D & C Violet No 2 during polymerisation of the lactide and glycolide. Suture may also be manufactured in the undyed form.

These sutures are relatively inert, nonantigenic, nonpyrogenic and elicit only a mild tissue reaction during absorption.

**Action** Two important characteristics describe the in vivo behaviour of absorbable sutures. The first of these is tensile strength retention and the second absorption rate or loss of mass.

Subcutaneous tissue implantation studies of both VICRYL and Coated VICRYL Suture in rats show at two weeks post-implantation approximately 55% of its original tensile strength remains, while at three weeks approximately 20% of its original strength is retained.

Intramuscular implantation studies in rats show that the absorption of these sutures is minimal until about the 40th post-implantation day. Absorption is essentially complete between the 60th and 90th days.

**Uses** VICRYL and Coated VICRYL synthetic absorbable sutures are intended for use where an absorbable suture or ligature is indicated.

**Dosage and Administration**  
By implantation.

**Contraindications, Warnings, etc.**  
These sutures, being absorbable, should not be used where extended approximation of tissues under stress is required.

Sutures placed in skin and conjunctiva may cause localised irritation if left in place for longer than 10 days and should be removed as indicated.

The safety and effectiveness of VICRYL (Polyglactin 910) and Coated VICRYL Sutures in neural tissue and in cardiovascular tissue have not been established.

**Pharmaceutical Precautions**  
Do not re-sterilise.

**Legal Category P** Pharmacy medicine sold to surgeons and hospitals through surgical dealers.

**Package Quantities** Various lengths of material packaged in sealed aluminium foil sachets. This primary pack is contained in a peel-apart secondary pack. The unit of sales is 12 packs contained in a film wrapped drawer style carton.

**Adverse Reactions** No suture related adverse reactions were reported during clinical trials, although a number of minor reactions were classified as being of unknown cause.

Product Licence Nos PL 0508/0001  
PL 0508/0009

---

**ETHICON LTD.**  
**PO BOX 408, BANKHEAD AVE**  
**EDINBURGH EH11 4HE**

---

\*Trademark

# GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE

LEADING FRENCH  
Journal in the field

GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE, official organ of the French National Gastroenterology Society and branches, publishes original clinical studies, papers in radiology and endoscopy, as well as reports on works in biology and experimental studies.

The Journal also publishes editorials, general reviews, thorough reviews, hypothesis, letters to the editor, books and papers reviews as French National Gastroenterology Society and branches reports.

The Editorial Board is composed of a gastroenterology section and of a hepatology section.

Papers on medical and surgical gastroenterology, hepatology and proctology are published in every issue. A special effort has been made to introduce topical reviews and editorials written by the best french and foreign specialists.

However, thematic editorials introducing a particularly important feature are regularly published.

GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE publishes within 7 to 10 weeks, letters to the editor which represent a valuable exchange between gastroenterologists.

These letters correspond either to important original facts, either to answers or comments about a study recently published in the journal.

GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE accepts studies written in cooperation in the fields of epidemiology, diagnosis and therapy.

GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE publishes its papers both French and English. Papers are written by authors of all nationalities confirming the Journal's international vocation.

Summaries are reproduced in « Current Contents » (series « Clinical Practice » and « Life Sciences »).

## EDITORIAL BOARD

- The Editor :  
C. Matuchansky  
(Poitiers).
- Associate Editor for  
Hepatology :  
D. Dhumeaux (Créteil).

## SUBSCRIPTION FORM

- ☐ Please enter my subscription\* to GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE (France : 518 FF, others countries : 128 \$).

Name : .....

Address : .....

- ☐ Enclosed the amount of : .....

France : send your payment to S.P.P.I.F., B.P. 22 - F 41350 VINEUIL.

Foreign countries : apply to S.P.P.I.F. for subscription rates and name of the exclusive agent.

\* All subscriptions run from January to December of the current year.

MASSON 